Aurinia Pharmaceuticals Inc. - Schedule 13D/A Filing

This Schedule 13D/A filing by Tang Capital Management LLC and associated entities amends a previous filing dated September 12, 2024. The amendment details transactions occurring since March 4, 2025, where the reporting persons have acquired an additional 2,200,000 shares of Aurinia Pharmaceuticals Inc. common stock through open market purchases, expending approximately $26.3 million. The filing restates the beneficial ownership as of the current date, with the reporting persons collectively owning 12,229,500 common shares, representing 9.2% of the outstanding shares. The transactions during the past 60 days, including purchases made between February 27, 2026, and March 3, 2026, are detailed in an attached exhibit, with purchase quantities and weighted average prices provided. No other person is disclosed as having the right to receive or direct the sale of these shares.